LeMaitre Vascular (NASDAQ:LMAT) Issues FY 2025 Earnings Guidance

Key Points

• LeMaitre Vascular has updated its FY 2025 earnings guidance, projecting earnings per share of $2.230-$2.370 and revenue between $248.0 million and $254.0 million, both higher than consensus estimates.
• The company's stock rose by 1.5% on the day of the announcement, with shares trading at $85.60 after reaching a one-year low of $71.42 and a high of $109.58.
• CEO George W. Lemaitre sold 76,868 shares of the company's stock, resulting in a 4.10% decrease in his ownership stake.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 2.230-2.370 for the period, compared to the consensus estimate of 2.154. The company issued revenue guidance of $248.0 million-$254.0 million, compared to the consensus revenue estimate of $245.5 million. LeMaitre Vascular also updated its Q3 2025 guidance to 0.540-0.590 EPS.

LeMaitre Vascular Price Performance

Shares of LMAT traded down $1.98 during trading hours on Friday, reaching $92.28. 149,596 shares of the company's stock traded hands, compared to its average volume of 146,164. The stock has a market cap of $2.09 billion, a PE ratio of 44.80, a price-to-earnings-growth ratio of 2.37 and a beta of 0.79. The company has a current ratio of 13.96, a quick ratio of 13.83 and a debt-to-equity ratio of 0.46. The firm's 50 day simple moving average is $83.35 and its 200-day simple moving average is $86.57. LeMaitre Vascular has a 12 month low of $71.42 and a 12 month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.57 by $0.03. The firm had revenue of $63.15 million during the quarter, compared to the consensus estimate of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%. The company's revenue for the quarter was up 15.0% on a year-over-year basis. During the same quarter last year, the company posted $0.52 EPS. Equities analysts expect that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 4th. Investors of record on Thursday, August 21st will be issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Thursday, August 21st. LeMaitre Vascular's dividend payout ratio (DPR) is currently 38.83%.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on LMAT shares. Barrington Research raised LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price objective on the stock in a report on Wednesday. Cantor Fitzgerald raised their price objective on LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a report on Wednesday. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $98.00.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 100,000 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $93.51, for a total value of $9,351,000.00. Following the transaction, the chief executive officer directly owned 1,727,003 shares of the company's stock, valued at $161,492,050.53. The trade was a 5.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders sold 200,000 shares of company stock worth $17,907,857. Company insiders own 9.50% of the company's stock.

Hedge Funds Weigh In On LeMaitre Vascular

A number of large investors have recently bought and sold shares of LMAT. Royal Bank of Canada increased its stake in LeMaitre Vascular by 1.5% in the 1st quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier's stock worth $9,579,000 after purchasing an additional 1,735 shares during the period. AQR Capital Management LLC increased its stake in LeMaitre Vascular by 36.4% in the 1st quarter. AQR Capital Management LLC now owns 27,878 shares of the medical instruments supplier's stock worth $2,339,000 after purchasing an additional 7,445 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in LeMaitre Vascular by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier's stock worth $1,013,000 after purchasing an additional 539 shares during the period. Millennium Management LLC increased its stake in LeMaitre Vascular by 119.8% in the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier's stock worth $17,722,000 after purchasing an additional 115,141 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in LeMaitre Vascular by 27.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier's stock worth $22,019,000 after purchasing an additional 55,804 shares during the period. 84.64% of the stock is owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.